Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Broadcom Inc (AVGO) vs Axogen Inc (AXGN) Price & Performance

Broadcom IncTrade
Axogen IncTrade

Price performance (Past 24H)

Key statistics

Broadcom Inc vs Axogen Inc — how do they compare? Broadcom Inc trades at $416.9 (market cap $1.98T), while Axogen Inc trades at $49.5 (market cap $2.61B). The key difference: Broadcom Inc is far larger — about 758.6× Axogen Inc's market cap, and Broadcom Inc pays a 0.62% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.

AVGOAXGN
Market Cap
$1.98T$2.61B
Sector
TechnologyTechnology
52-Week High
$481.57$48.48
52-Week Low
$289.60$14.16
Enterprise Value
$2.02T$2.52B
Dividend Yield
0.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Broadcom Inc

Broadcom (AVGO) trades at $419.67, down 0.65% on the day, with a bullish technical signal from moving averages and strong support at $412. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $2.44 exceeding the $2.40 estimate. Revenue grew to $63.89 billion in 2025, and net income surged to $23.13 billion, reflecting a 36.19% margin. Analysts maintain a strong buy consensus, with a $510.21 price target, citing AI-driven growth prospects.

The outlook for AVGO remains positive, driven by AI semiconductor demand and solid cash flow generation. However, high valuation multiples like a P/E of 69.23 pose risks if growth slows. Competitive pressures in the chip industry and macroeconomic volatility could challenge future performance, but institutional confidence and consistent earnings strength support a favorable investment case for long-term holders.

Axogen Inc

AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.

The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Broadcom Inc

Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.

Read more on AVGO

About Axogen Inc

Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.

Read more on AXGN